Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Arteries vs veins: which graft keeps hearts beating longer?

NCT ID NCT07057713

Disease control Sponsor: Second Hospital of Jilin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two surgical techniques for coronary artery bypass grafting (CABG). One uses only arteries (total arterial grafting), while the other uses a mix of artery and vein grafts (conventional mixed grafting). The goal is to see which approach keeps grafts open longer and reduces heart complications. About 400 adults with multivessel coronary artery disease will take part, and their grafts will be checked after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Coronary artery bypass grafting (CABG) using either total arterial grafts (internal thoracic and radial arteries) or mixed grafts (internal thoracic and saphenous vein)
What this could lead to
If total arterial grafting proves better, it could lead to longer-lasting bypass grafts and fewer future heart problems for people with coronary artery disease.
What could go wrong
This is a single-center trial with 400 participants, so results may not apply to all patients. The study only follows patients for 12 months, and long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Diagnosed with multivessel coronary artery disease 3. Indicated for elective coronary artery bypass grafting (CABG) involving ≥3 coronary vessels 4. Right coronary artery stenosis \>75% 5. Able and willing to provide written informed consent Exclusion Criteria: 1. Scheduled for concurrent cardiac procedures (e.g., valve surgery, congenital heart disease repair, aortic dissection surgery, atrial fibrillation ablation) 2. Severe stenosis of left or right subclavian artery 3. Unsuitable saphenous veins (e.g., bilateral varicosities) 4. Unsuitable radial artery as assessed preoperatively 5. History of intracranial hemorrhage or ischemic stroke within the past 14 days 6. Severe hepatic or renal insufficiency 7. Acute myocardial infarction within 72 hours prior to surgery 8. History of prior CABG or other cardiac surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial graft are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial graft Coronary artery bypass grafting Coronary artery disease Graft patency Major adverse cardiovascular events

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Hospital of Jilin University

    Changchun, Jilin, 130000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.